Assess from research through manufacture
Knowledge of a substance may be limited during early development. This uncertainty must be reflected in assessment and measures, rather than interpreting absent data as absence of danger.
INSST’s NTP 1210 highlights that pharmacological activity also matters for occupational exposure. Inhalation or dermal exposure may differ from therapeutic administration, so a workplace limit cannot be derived from a treatment dose.
Categories and internal guidance values
Categorisation systems connect hazard information with control strategies. Their application requires technical judgement and adaptation to the substance and process; it is not assigning a label based on commercial similarity.
Internal occupational exposure guidance values are not legally equivalent to official limit values. Identify their source, rationale and scope rather than present them as universal regulatory limits.
Containment and tasks that open the process
The hierarchy of controls guides measure selection. Transfers, sampling, filter changes and cleaning need particular attention because they can alter containment intended for normal production.
Engineering controls, ventilation and procedures must work together. Personal protection depends on residual risk and the task. A measure designed for one process does not automatically transfer to another product.
Biological processes and new developments
Biomanufacturing may involve organisms or materials with specific risks. NIOSH highlights the need to assess exposure when moving from laboratory to industrial scale and to verify containment measures.
Scaling up requires review of equipment, tasks and exposed people. Reproducing a laboratory instruction is insufficient if quantities, duration or intervention methods change.
Cleaning, maintenance and follow-up
Maintenance safety must include information on materials present and intervention conditions. Cleaning protects the process but can also expose staff to substances or residues requiring control.
Training must explain measures and limits of action. Health surveillance is organised according to risks and with confidentiality, without replacing exposure reduction or serving as the sole effectiveness check.
Hypothetical example: introducing an active ingredient
Before introducing an active ingredient, a company gathers available information, identifies contact tasks and reviews containment capacity. A competent team decides controls and documents uncertainties.
When new data arrives, the decision is reviewed. Medicine authorisation is not used as proof of manufacturing safety. Whether working conditions protect the people producing it is checked separately.
